Duquesne University School of Pharmacy Sewickley, Pennsylvania
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm that is defined by the presence of the Philadelphia chromosome. The discovery of the breakpoint cluster region (BCR)-Abelson murine leukemia (ABL) 1 fusion oncogene has revolutionized the treatment of this disease. The prognosis of patients with chronic phase CML has improved exponentially with the development of oral tyrosine kinase inhibitors (TKIs), which lead to fast and deep molecular remissions. However, optimal treatment of CML includes considerations of patient comorbidities, adequate recognition and management of adverse events, careful monitoring for treatment response, and an understanding of the patient’s treatment goals. Promising new agents have been developed for patients who develop resistance to front-line therapies, and treatment-free remission (TFR) after discontinuing TKIs has recently become a new goal for CML treatment.
Learning Objectives:
Examine the most recent clinical data and guideline recommendations to personalize treatment for patients with chronic myelogenous leukemia (CML)
Differentiate between the recommended treatments of CML based on pharmacology and adverse effect profiles
Determine strategies to minimize adverse effects and optimize care for patients receiving treatment for CML